Vaginal estrogen safety under scrutiny: new study targets blood clot risk

NCT ID NCT07160504

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether vaginal estrogen tablets, used to treat vaginal atrophy, change blood clotting factors in postmenopausal women. Researchers will take blood samples before and after 3 months of treatment. The goal is to see if this common treatment might raise or lower the risk of blood clots, especially in women who have had a clot before.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

vaginal estradiol tablets

What this could lead to

If it works, this could clarify whether local vaginal estrogen is safe for women with a history of blood clots.

What could go wrong

This is a small, early-phase study focused on lab markers, not clinical outcomes. Results may not change current practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VAGINA ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postmenopausal atrophic vaginitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Obstetrics and Gynecology, Aarhus University Hospital, Denmark

    RECRUITING

    Aarhus N, 8200, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••